Literature DB >> 23639793

The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia.

Loukia M Spineli1, Stefan Leucht, Andrea Cipriani, Julian P T Higgins, Georgia Salanti.   

Abstract

UNLABELLED: Patient dropout is common in mental health trials. It is important to understand why patients drop out from trials, so that measures can be taken to minimize its occurrence. This research sought to identify trial characteristics that have an impact on premature discontinuation in antipsychotic trials for schizophrenia.
METHODS: Poisson regression analysis was applied with dropout rate per patient-week as the dependent variable and trial characteristics as independent variables. Multinomial logistic regression analysis was performed to examine whether the same characteristics predict whether patients drop out without providing any outcome data and whether they drop out with sufficient early data for a 'last observation carried forward' analysis to be performed.
RESULTS: trials with adequate allocation concealment, double blinding, placebo as control, higher precision, larger trial size, at least three treatment arms, recent publication, conduct in the United States and enrollment of inpatients were all associated with higher dropout rates. Similar factors were associated with whether a patient was more likely to be evaluated at least once, or be excluded entirely from the analysis. However, blinding status did not predict the former type of dropout, and allocation concealment, higher precision and larger sample size, number of arms, recent publication and recruiting inpatient did not predict the latter type of dropout.
CONCLUSIONS: high dropout rates in antipsychotic trials can be associated with various characteristics, and appears to be particularly associated with use of placebo and study size.
© 2013 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Completers; Dropout; Excluded; Last observation carried forward; Missing data; Randomized controlled trials

Mesh:

Substances:

Year:  2013        PMID: 23639793     DOI: 10.1016/j.euroneuro.2013.03.006

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  7 in total

1.  Dose equivalents for second-generation antipsychotics: the minimum effective dose method.

Authors:  Stefan Leucht; Myrto Samara; Stephan Heres; Maxine X Patel; Scott W Woods; John M Davis
Journal:  Schizophr Bull       Date:  2014-02-03       Impact factor: 9.306

2.  Continuous(ly) missing outcome data in network meta-analysis: A one-stage pattern-mixture model approach.

Authors:  Loukia M Spineli; Chrysostomos Kalyvas; Katerina Papadimitropoulou
Journal:  Stat Methods Med Res       Date:  2021-01-06       Impact factor: 3.021

3.  Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder.

Authors:  Woo-Young Jung; Sae-Heon Jang; Sung-Gon Kim; Young-Myo Jae; Bo-Geum Kong; Ho-Chan Kim; Byeong-Moo Choe; Jeong-Gee Kim; Choong-Rak Kim
Journal:  Psychiatry Investig       Date:  2016-07-25       Impact factor: 2.505

4.  Safety and effectiveness of long-acting versus intermediate-acting insulin for patients with type 1 diabetes: protocol for a systematic review and individual patient data network meta-analysis.

Authors:  Areti Angeliki Veroniki; Sharon E Straus; Huda M Ashoor; Jemila S Hamid; Catherine Yu; Andrea C Tricco
Journal:  BMJ Open       Date:  2015-12-30       Impact factor: 2.692

5.  Recruitment and retention strategies in mental health trials - A systematic review.

Authors:  Yifeng Liu; Emma Pencheon; Rachael Maree Hunter; Joanna Moncrieff; Nick Freemantle
Journal:  PLoS One       Date:  2018-08-29       Impact factor: 3.240

6.  A systematic survey shows that reporting and handling of missing outcome data in networks of interventions is poor.

Authors:  Loukia M Spineli; Juan J Yepes-Nuñez; Holger J Schünemann
Journal:  BMC Med Res Methodol       Date:  2018-10-24       Impact factor: 4.615

7.  Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis.

Authors:  Dimitris Mavridis; Ian R White; Julian P T Higgins; Andrea Cipriani; Georgia Salanti
Journal:  Stat Med       Date:  2014-11-13       Impact factor: 2.373

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.